#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Follicular lymphoma stage III Intracranial germ cell tumour Kearns-Sayre syndrome Pulmonary hypertension SAPHO syndrome Small intestine adenocarcinoma Breast cancer metastatic Sickle cell disease Liposarcoma metastatic White matter lesion Anal cancer Fibrous dysplasia of bone Sarcoidosis Leukoencephalopathy Neuroendocrine carcinoma More trials…

    Learn about Rare Diseases

    Rhabdomyosarcoma – Basic Information Pemphigus – Life with Disease Testicular leiomyosarcoma – Diagnostics Myxofibrosarcoma – Diagnostics Wiskott-Aldrich syndrome – Trials in Disease Alternating hemiplegia of childhood – Life with Disease Noonan syndrome Angiosarcoma recurrent – Basic Information Sarcoidosis – Trials in Disease Leiomyosarcoma recurrent – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    COBALAMIN Belantamab Mafodotin Cariprazine Hydrochloride Caraway Oil Rbd1016 Dexamethasone Phosphate Rbd5044 Sodium Mva-209-Fsp-B3 Gs-4182 TIFCEMALIMAB DESMOPRESSIN ACETATE Fampridine Pemetrexed Disodium Mometasone Furoate Ph. Eur. Eprosartan Mesilate Fidanacogene Elaparvovec Vx-670 Fexofenadine Hydrochloride Sar444656 Vamorolone More therapies…

    Learn about Your Condition

    Netherton's syndrome Open angle glaucoma Obliterative bronchiolitis Fatty acid oxidation disorder Chronic coronary syndrome Abdominal pain Varices oesophageal Injection site pain Metastases to peritoneum Insulin resistance Systemic lupus erythematosus Exposure via breast milk Aortic stenosis Myositis Neurodevelopmental disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Transplant rejection

  • A Study of Belimumab to Help Identify Safe Kidney Transplant Matches in Patients with High Antibody Levels Against Donor Tissue Types

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Belimumab
    The Netherlands

  • Study on Allogeneic Umbilical Cord Mesenchymal Stromal Cells for Treating Chronic Kidney Transplant Rejection in Adult Patients

    Not yet recruiting

    4 1
    Investigated Diseases:
    • Transplant rejection
    Investigated Drugs:
    • ALLOGENEIC UMBILICAL CORD TISSUE-DERIVED MESENCHYMAL STROMAL CELLS EX VIVO EXPANDED
    France

  • A study testing ALXN2030 for adults with antibody-mediated rejection after kidney transplantation

    Not recruiting

    2 1
    Investigated Diseases:
    • Transplant rejection
    Investigated Drugs:
    • RNA, (AM-SP-UM-CM-AM-AM-CM-UM-(2′-DEOXY-2′-FLUORO)C-(2′-DEOXY-2′-FLUORO)A-(2′-DEOXY-2′-FLUORO)C-(2′-DEOXY-2′-FLUORO)C-UM-GM-UM-AM-AM-UM-AM-AM-AM-GM-CM-AM-GM-CM-CM-GM-[2′-O-[[2-[2-[[5-[[2-(ACETYLAMINO)-2-DEOXY-BETA-D-GALACTOPYRANOSYL]OXY]-1-OXOPENTYL]AMINO]ETHOXY]ETHOXY]METHYL]]A-[2′-O-[[2-[2-[[5-[[2-(ACETYLAMINO)-2-DEOXY-BETA-D-GALACTOPYRANOSYL]OXY]-1-OXOPENTYL]AMINO]ETHOXY]ETHOXY]METHYL]]A-[2′-O-[[2-[2-[[5-[[2-(ACETYLAMINO)-2-DEOXY-BETA-D-GALACTOPYRANOSYL]OXY]-1-OXOPENTYL]AMINO]ETHOXY]ETHOXY]METHYL]]A-GM-GM-CM-UM-GM-CM), COMPLEX WITH RNA ([4′-DE(HYDROXYMETHYL)-4′-[(HYDROXYMETHOXYPHOSPHINYL)METHOXY]]UM-SP-(2′-DEOXY-2′-FLUORO)U-SP-(2′-DEOXY-2′-FLUORO)U-(2′-DEOXY-2′-FLUORO)A-(2′-DEOXY-2′-FLUORO)U-UM-(2′-DEOXY-2′-FLUORO)A-CM-AM-(2′-DEOXY-2′-FLUORO)G-GM-UM-GM-(2′-DEOXY-2′-FLUORO)A-GM-UM-UM-GM-AM-UM-SP-GM-SP-GM)
    Spain

  • Study on Riliprubart for Preventing and Treating Antibody-Mediated Rejection in Adult Kidney Transplant Patients

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Transplant rejection
    Investigated Drugs:
    • Riliprubart
    France Germany Italy Spain Sweden

  • Study on Efgartigimod for Patients with Antibody-Mediated Rejection after Kidney Transplant

    Not recruiting

    2 1
    Investigated Drugs:
    • Efgartigimod Alfa
    Austria Belgium Czechia France Germany Spain

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!